This article is more than 5 years old. Information may no longer be current.
VIDEO: ‘Transformative’ ASCO abstracts highlight progress with biomarkers, targeted therapies
Click Here to Manage Email Alerts
CHICAGO — The ASCO Annual Meeting featured several “transformative” abstracts, according to Edward S. Kim, MD, chairman of solid tumor oncology at Levine Cancer Institute at Carolinas HealthCare System and a HemOnc Today Editorial Board member.
“It’s really quite cool to say how abstracts over the last decade have evolved,” Kim said. “This year, we’re not talking about phase 3 trials with marginal benefits or cytotoxic chemotherapies that may add a seventh or eighth treatment to a different tumor type. These days, we’re talking about biomarkers and the ways we can obtain [them].”
Kim discusses the importance of biomarkers, targeted therapies and precision medicine.
He also describes the TAPUR study, an ASCO-led clinical trial designed to assess the use of FDA–approved, molecularly targeted cancer therapies in patients with advanced cancers that may have actionable genomic variants.